We could not identify a study that focused on e2 and PET-based tau outcomes, though future studies using both PET amyloid and tau may help clarify the role of e2 on the development of AD biomarkers, particularly based on the amyloid cascade hypothesis (Jack et al., 2010). This evidence concerns the gene MAPT and Alzheimer disease.